Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 31917.01 
• Atom Count: 1911 
• Residue Count: 272 
• Unique protein chains: 1

2X81

STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054

• DOI: 10.2210/pdb2X81/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda


• Deposited: 2010-03-05 Released: 2010-05-05 
• Deposition Author(s): Savory, W., Mueller, I., Mason, C.S., Lamers, M., Williams, D.H., Eyers, P.A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.91 Å
• R-Value Free: 0.303 
• R-Value Work: 0.244 

Literature

Drug-Resistant Aurora a Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors Mln8054 and Mln8237.

Sloane, D., Trikic, M., Chu, M.L., Lamers, M., Mason, C.S., Mueller, I., Savory, W., Williams, D.H., Eyers, P.A.

(2010) Acs Chem.Biol. 5: 563

• PubMed: 20426425 
• DOI: 10.1021/cb100053q


• PubMed Abstract: 
  

The Aurora kinases regulate multiple aspects of mitotic progression, and their overexpression in diverse tumor types makes them appealing oncology targets. An intensive research effort over the past decade has led to the discovery of chemically distinct families of small molecule Aurora kinase inhibitors, many of which have demonstrated therapeutic potential in model systems. These agents are also important tools to help dissect signaling pathways that are orchestrated by Aurora kinases, and the antiproliferative target of pan-Aurora inhibitors such as VX-680 has been validated using chemical genetic techniques. In many cases the nonspecific nature of Aurora inhibitors toward unrelated kinases is well established, potentially broadening the spectrum of cancers to which these compounds might be applied. However, unambiguously demonstrating the molecular target(s) for clinical kinase inhibitors is an important challenge, one that is absolutely critical for deciphering the molecular basis of compound specificity, resistance, and efficacy. In this paper, we have investigated amino acid requirements for Aurora A sensitivity to the benzazepine-based Aurora inhibitor MLN8054 and the close analogue MLN8237, a second-generation compound that is in phase II clinical trials. A crystallographic analysis facilitated the design and biochemical investigation of a panel of resistant Aurora A mutants, a subset of which were then selected as candidate drug-resistance targets for further evaluation. Using inducible human cell lines, we show that cells expressing near-physiological levels of a functional but partially drug-resistant Aurora A T217D mutant survive in the presence of MLN8054 or MLN8237, authenticating Aurora A as a critical antiproliferative target of these compounds.

---

Organizational Affiliation: 

Yorkshire Cancer Research Institute for Cancer Studies, University of Sheffield, UK.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
SERINE/THREONINE-PROTEIN KINASE 6	A	272	Homo sapiens	Mutation(s): 0  Gene Names: AURKA (AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6) EC: 2.7.11.1
Find proteins for O14965 (Homo sapiens) Go to Gene View: AURKA Go to UniProtKB:  O14965

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
ZZL	A	4-{[9-CHLORO-7-(2,6-DIFLUOROPHENYL)-5H-PYRIMIDO[5,4-D][2]BENZAZEPIN-2-YL]AMINO}BENZOIC ACID C25 H15 Cl F2 N4 O2 HHFBDROWDBDFBR-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
ZZL	IC50: 1 - 34 nM (100) BINDINGDB
ZZL	Ki: 7 nM (94) BINDINGDB
ZZL	Kd: 6.5 - 6500 nM (100) BINDINGDB
ZZL	IC50: 5 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.91 Å
• R-Value Free: 0.303 
• R-Value Work: 0.244 
• Space Group: P 6₁ 2 2

Unit Cell:

Length (Å)	Angle (°)
a = 83.210	α = 90.00
b = 83.210	β = 90.00
c = 167.241	γ = 120.00

Software Package:

Software Name	Purpose
REFMAC	refinement
MOSFLM	data reduction
SCALA	data scaling
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2010-03-05 
• Released Date: 2010-05-05 
• Deposition Author(s): Savory, W., Mueller, I., Mason, C.S., Lamers, M., Williams, D.H., Eyers, P.A.

Revision History 

• Version 1.0: 2010-05-05
  Type: Initial release
• Version 1.1: 2011-08-31
  Type: Database references, Source and taxonomy, Version format compliance
• Version 1.2: 2017-06-28
  Type: Data collection